The fracture predisposition of women treated with the insulin-sensitizing drugs thiazolidinediones (TZDs), which activate the nuclear receptor peroxisome proliferator-activated receptor-γ (PPAR-g), is a major skeletal complication of metabolic syndrome 1 . Thus, the means by which TZDs and PPAR-g affect bone cells have come under particular scrutiny. For example, it is thought that PPAR-g is essential for physiological osteoclastogenesis, and that pharmacological induction of these bone-resorptive cells is a (the) principal means by which TZDs promote fracture 2,3 . However, the conclusion that PPAR-g mediates physiological osteoclast formation was presented by a study in which the gene encoding PPAR-g, Pparg, was deleted in myeloid-lineage cells-from which the osteoclast is derived-by using endothelial-specific receptor tyrosine kinase (Tek, also known as Tie2)-Cre 2 . Because this recombinase also targets endothelium 4 , we asked whether the same skeletal phenotype would emerge from more myeloid-specific Cre recombinases. To this end, we crossed Pparg fl/fl mice to those expressing two copies of lysozyme M (LysM) promoter (LysM-Cre +/+ ) (LysM knockout (KO)), which exclusively targets myeloid cells, including those of osteoclast lineage 5 . Naïve LysM-Cre +/+ (Cont) mice served as controls. As demonstrated by fluorescence-activated cell sorting (FACS), PPAR-g deletion by LysM-Cre does not affect the abundance of marrow-residing, committed osteoclast, granulocyte and macrophage progenitors (GMPs) (data not shown). Bone marrow macrophages (BMMs) were then induced to undergo osteoclastogenesis by macrophage colony-stimulating factor (M-CSF) and RANK ligand (RANKL). PPAR-g abundance diminishes with osteoclast differentiation in control mice but is virtually undetectable, regardless of the duration of exposure to osteoclastogenic cytokines, in LysM KOs (Fig. 1a) . Predictably, osteoclastogenic differentiation marker protein expression increases with exposure to the cytokines. These proteins are, however, similarly expressed in the presence and absence of PPAR-g. Importantly, the induction of c-Fos, postulated to mediate the putative physiological, osteoclast-forming properties of PPAR-g (ref.
support of histomorphometry, trabecular bone volume and the parameters of cancellous architecture are similar in both groups (Fig. 1d) .
These data establish that LysM-Cre-mediated deletion of PPAR-g alters neither physiological osteoclastogenesis nor skeletal architecture. To examine this issue in a pathological context, we asked whether the same applies to estrogen deficiency. Thus, female mice were ovariectomized or subjected to sham surgery. Four weeks later, skeletal parameters were quantified by μCT. As expected, ovariectomy reduced trabecular bone volume by approximately one-third in control mice relative to sham-operated mice ( Supplementary Fig. 1c ). The same magnitude of osteoporosis occurred, however, in their LysM KO counterparts. Next, we induced K/ BxN serum-transfer inflammatory arthritis in both groups of animals 4 . As seen in Supplementary Figure 1d , osteoclast abundance seems to be identical in mice with arthritis, regardless of the presence of PPAR-g in myeloid-lineage cells.
Given the inconsistency of the effects of LysM-Cre deletion of PPAR-g on osteoclastogenesis with that reported to accompany Tie2-Cre deletion 2 , we bred male Tie2-Cre-Pparg fl/wt to female Pparg fl/fl mice (Tie2 KO). As reported, Tie2 KO mice have a significant increase in spleen weight relative to body mass, as compared to control mice (P < 0.05) (Supplementary Fig. 2a ). Similarly to LysM KO mice, the abundance of marrow-residing, committed GMP osteoclast precursors was virtually unaltered by Tie2-Cre-mediated deletion (data not shown). Moreover, the osteoclastogenic capacity in vitro and in vivo and the bone masses of Tie2-Cre + -Pparg fl/fl mice were essentially identical to those of their Cont counterparts (Fig. 1e-h) . We extended these studies to the Tie2-Cre-Pparg fl/fl mice used by Wan et al. 2 in the original study of the role of the nuclear receptor on murine osteoclastogenesis (Tie2 original ). Again, we observed normal osteoclast formation in vitro and unaltered bone mass ( Supplementary Fig. 2b-d) , as well as an absence of a pale bone phenotype (Supplementary Fig. 2e) . Finally, to confirm the lack of effect of PPAR-g deletion on physiological osteoclast formation, we crossed Pparg fl/fl mice with those expressing RANK-Cre or Vav1-Cre. The former targets all osteoclast lineage cells 6 , and the latter targets hematopoietic stem cells and thus all their derivatives 7 . In both circumstances, we observed no effect on the bone-resorptive cells (Supplementary Fig.  2f-l) . All Cre recombinases reduced Pparg mRNA by more than 99%, confirming the absence of mosaicism (data not shown).
TZDs bind PPAR-g, and it has been long assumed that these drugs promote insulin sensitivity via the activation of this adipogenic nuclear receptor. Recent evidence, however, challenges this supposition 8 . Thus, a TZD with low PPAR-g affinity promotes glucose sensitivity as effectively as its standard counterparts 9 . Unlike the TZD rosiglitazone, the same PPAR-g-sparing TZD fails to induce osteoporosis in mice 3 . Providing confirmation that, unlike physiological or pathological osteoclastogenesis, PPAR-g mediates pharmacological induction of bone-resorptive cells, rosiglitazone-stimulated osteoclast differentia-PPAR-γ regulates pharmacological but not physiological or pathological osteoclast formation CO R R E S P O N D E N C E METHODS Methods and any associated references are available in the online version of the paper. 
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The authors declare no competing financial interests. tion-as determined by cathepsin K expression-is arrested in LysM KO BMMs (Fig. 1i) .
These data call into question the concept that PPAR-g mediates osteoclast generation in physiological or pathological conditions. Similarly, the normal differentiation of PPAR-g-deficient precursors is inconsistent with the supposition that osteoclast progenitors reside almost exclusively in PPAR-g-expressing cells 10 . They also challenge our conclusion that the polycomb protein ASXL2 stimulates osteoclast formation in a cellautonomous manner by serving as a PPAR-g co-activator, which in turn raises the possibility that non-osteoclast-autonomous mechanisms exert a more profound influence than previously appreciated 11 . Regardless of the lack of effect of PPAR-g on basal and pathological osteoclastogenesis, it is central to pharmacologically induced bone resorption, and thus contributes to the fracture-producing properties of TZDs. 
Evans and Wan reply:
This concerns the correspondence by Zou et al. 1 on the physiologic, pharmacologic and pathologic roles of peroxisome proliferator-activated receptor-γ (PPAR-g) in osteoclasts. Multiple studies, including our own 2 and that of Zou et al. 1 , demonstrate a direct role for PPAR-g in enhancing osteoclastogenesis, which would in part explain the increase in bone fractures seen in patients treated with PPAR-g drugs, such as Actos or Avandia, as compared to untreated controls. Thus, the suggestion by Zou et al. 1 that PPAR-g does not regulate normal osteoclast differentiation is unexpected and inconsistent with our findings that PPAR-g deficiency leads to osteoclast dysfunction and osteopetrosis 2 .
The burden of proof to support the 'serendipitous' expression of PPAR-g in osteoclasts is high, given its agreed-upon potent pro-osteoclastogenic activity. In our hands, the genetic loss of PPAR-g in the osteoclast lineage leads to splenomegaly and extramedullary hematopoiesis (EMH), a phenotype consistent with a major role in osteoclastogenesis. Indeed, splenomegaly and EMH are hallmarks of osteoclast defects in multiple osteopetrotic mouse models [3] [4] [5] [6] [7] [8] . Furthermore, osteopetrosis, EMH and splenomegaly are pathologically linked in humans 9 , and spleen enlargement is a key clinical symptom used for the diagnosis of osteopetrosis in patients 10 . In our original study 2 , this phenotype was both conferred and rescued by bone marrow transplants, an observation that is consistent with a defect in the marrow. Of note, Zou et al. 1 confirmed our findings 2 and reported the same splenomegaly in their PPAR-g knockout (KO) mice (~50% increase in spleen/body weight ratio; see Supplementary Figure 2a in Zou et al. 1 ) when they used the same Tie2-Cre as in our study 2 . Unfortunately, in Zou et al. 1 , the importance of this phenotype was not discussed, and the spleen sizes in the Vav1-and LysM-PPAR-g KO mice were not provided. Similarly, Zou et al. 1 confirmed our findings and reported reduced expression of Ctsk, an osteoclast differentiation marker and a protease responsible for bone degradation, in LysM-Cre PPAR-g KO mice as compared to wild-type controls; however, they did not address the significance or relevance of this result. Moreover, other osteoclast differentiation markers (Acp5, Calcr, Car2, MMP9) that exhibited greater reductions (>80%) in basal expression in the Tie2-Cre PPAR-g-KO in our original report 2 were not interrogated by Zou et al. 1 . Importantly, Zou et al. 1 did not report serum levels of boneresorption markers-in vivo measurements of osteoclast activity.
In the penultimate sentence of their correspondence 1 , the authors allude to a conflict with their own recently published results in Izawa et al. 11 . This intriguing study on the PPAR-g co-factor ASXL2 leads them to conclude that "ASXL2 regulates the osteoclast via two distinct signaling pathways. It induces osteoclast formation in a PPARg/c-Fos-dependent manner and is required for RANK ligand-and thiazolidinedione-induced bone resorption independent of PGC-1b", which is in agreement with our original study 2 . Izawa et al. 11 reported osteopetrosis in ASXL2-KO mice with splenomegaly and high bone mass, which is similar to the phenotype of our Tie2-Cre PPAR-g-KO mice 2 . By contrast, the opposite phenotype for ASXL2-KO (bone loss rather than bone gain) was reported by this group in an earlier study in Farber et al. 12 . These apparent discrepancies highlight the challenges and potential pitfalls in loss-and gain-of-function studies. For example, although fibroblast growth factor 1 (FGF1) is widely used in growth media, the lack of any developmental, reproductive, neurologic or cardiovascular defects in the FGF1-knockout mouse might be considered as proof of no physiologic function of the protein. However, 15 years after the KO mouse was developed, an essential role for FGF1 in the survival of nutrient stress was eventually described by Jonker et al. 13 .
It is possible that subtle changes in culture conditions or the genetic background of the mice could explain some of the variations in PPAR-g gain-and loss-of-function studies. On this note, our mice could not be fully inbred, which might lead to some intrinsic genetic variation during the 9 years between the two studies. In addition, Tie2-Cre, Vav1-Cre and LysM-Cre each knock out PPAR-g at different developmental times and in different sets of cells. Thus, timing and cell cross-talk could produce variable phenotypes both in vitro and in vivo.
Despite some hard-to-reconcile differences, the suggestion that PPAR-g is irrelevant to osteoclast function, although possible, is not logical. On balance, the data supports a physiologic role for PPAR-g in osteoclastogenesis; however, clearly more work needs to be done. Given the established translational impact of pharmacologically activated PPAR-g on bone loss, additional and careful examination of the differences will no doubt be enlightening.
